Loading
Life sciences · Phase 4 Trial
ClinicalTrials.gov · October 26, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 4 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07893457). This is a study registration, not published results. Lead sponsor: Mayo Clinic. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE4. Study type: INTERVENTIONAL. Enrollment: 30 participants (ESTIMATED). Conditions: Obese Adults. Interventions: DRUG: Placebo; DRUG: Tirzepatide. Primary outcome measures: Total Esophageal Acid Exposure Time During 96-Hour Wireless pH Monitoring , During the 96-hour wireless pH monitoring period, completed within 40 days after enrollment.. Brief summary: This study will assess whether a single subcutaneous dose of tirzepatide 7.5 mg , compared with saline placebo, increases total esophageal acid exposure time during a 96-hour wireless pH recording beginning about 48 hours after study medication.